Skip to main content
Virbac logo

Virbac — Investor Relations & Filings

Ticker · FR000 ISIN · FR0000031577 LEI · 969500QQ1X5XHG649644 PA Manufacturing
Open in API
Filings indexed 975 across all filing types
Latest filing 2011-04-19 Earnings Release
Country FR France
Listing PA FR000

About Virbac

https://corporate.virbac.com/home.html

Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Founded in 1968 by a veterinarian, the company provides veterinarians, farmers, and pet owners with a comprehensive range of products and services. Its portfolio of innovative solutions covers the majority of animal species and diseases, with a focus on both companion and farm animals. Key product areas include vaccines, dermatology, parasite control, dental care, nutrition, and diagnostics. Through its international R&D network, Virbac develops solutions to prevent, diagnose, and treat animal pathologies, contributing to animal welfare and supporting sustainable farming.

Recent filings

Filing Released Lang Actions
Forte croissance du chiffre d'affaires au premier trimestre
Earnings Release Classification · 98% confidence The document is titled "FORTE CROISSANCE DU CHIFFRE D'AFFAIRES AU PREMIER TRIMESTRE" (Strong Revenue Growth in the First Quarter) and is dated April 19, 2011. It provides key financial highlights for the first quarter (Q1) of the fiscal year, including consolidated revenue (€159.9 M), organic growth rates by geography and segment (companion animals, livestock), and the impact of recent acquisitions. This content structure—a brief announcement focusing only on key performance indicators for a specific short period (a quarter)—is characteristic of an Earnings Release (ER), which typically precedes the more comprehensive Interim Report (IR). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR) as it only provides highlights and summary figures, not detailed financial statements. It is not a Call Transcript (CT) or Investor Presentation (IP). Therefore, the most appropriate classification is Earnings Release (ER). The document length (2082 chars) is short, but it contains the core results, making it the release itself, not just an announcement of a release (RPA). Q1 2011
2011-04-19 French
Déclaration d'actions et de droits de vote au 31 Mars 2011
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "DECLARATION D'ACTIONS ET DE DROITS DE VOTE" (Declaration of Shares and Voting Rights) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and the total gross and net voting rights as of a specific date (March 31, 2011). This content directly relates to the official declaration of voting rights and capital structure, matching the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is a declaration, it is the primary document containing the voting rights information, not just an announcement of results from a meeting, making DVA the most precise fit over AGM-R or DVA (which usually implies results *after* a vote). Given the content is the declaration itself, DVA is appropriate.
2011-04-05 French
Declaration of the number of shares and voting rights as of March 31, 2011
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled 'DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS' and explicitly references Article 223-16 of the French Financial Market Authority (AMF) regulations. It provides a table detailing the total number of shares and the corresponding gross and net total voting rights as of a specific date (March 31, 2011). This content directly relates to the official declaration of voting rights and share capital structure, which aligns precisely with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not an AGM presentation, a full annual report, or a management change announcement.
2011-04-05 English
LEISHMANIOSE CANINE : le vaccin CaniLeish® * obtient un enregistrement européen
Regulatory Filings Classification · 95% confidence The document is a press release dated March 17, 2011, announcing that the European Medicines Agency (EMA) and the European Commission have granted a European Marketing Authorization (AMM) for the veterinary vaccine CaniLeish® against canine leishmaniasis. This announcement concerns a significant regulatory approval and market entry for a new product. It is not a standard periodic financial report (10-K, IR, ER), a management change (MANG), or a director's trade (DIRS). Since it announces a specific regulatory/product development milestone that doesn't fit the other specific categories (like M&A, Capital Change, Dividend), it falls best under the general 'Regulatory Filings' category as a significant, non-standard announcement, or potentially 'LTR' if viewed as a regulatory outcome, but 'RNS' is the best fit for general regulatory announcements not covered elsewhere. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate classification for this specific regulatory approval announcement that isn't a standard financial filing or a specific corporate action like a merger or share issue.
2011-03-17 French
CANINE LEISHMANIOSIS: the CaniLeish® * vaccine obtains a European registration
Regulatory Filings Classification · 95% confidence The document is a press release dated March 17, 2011, announcing that the European Commission awarded Virbac a European registration for its CaniLeish® vaccine following a favorable opinion from the EMA's CVMP. This is a specific announcement regarding a regulatory approval for a product. It is not a standard periodic financial report (10-K, IR, ER) or a general regulatory filing (RNS). It details a specific corporate event related to product approval and initial launch plans. Given the options, this type of announcement, which is not a standard financial filing but a significant corporate/product update, fits best under the general 'Regulatory Filings' (RNS) category as a specific regulatory milestone announcement, or potentially 'LTR' if viewed as a regulatory outcome, but RNS is the best general fit for non-standard regulatory news releases that aren't explicitly covered elsewhere (like M&A or Director Dealing). Since it is a specific regulatory milestone announcement, and RNS is the fallback for miscellaneous regulatory announcements, I will classify it as RNS.
2011-03-17 English
Historic growth of sales and net earnings
Earnings Release Classification · 98% confidence The document is titled '2010 RESULTS' and provides a detailed summary of consolidated financial figures for the year 2010 compared to 2009, including Revenue, Operating Result, and Net Result. It explicitly mentions that 'The financial statements have been audited.' This content structure—a summary of annual financial performance highlights—is characteristic of an Earnings Release (ER) or the summary section preceding a full Annual Report (10-K). Since it presents key figures and analysis but is relatively brief (under 5200 characters) and focuses on the *release* of the results, it aligns best with an Earnings Release (ER). It is not a full 10-K, nor is it a transcript (CT) or a management discussion (MDA), although it contains elements of MDA. The mention of a dividend proposal for the 'next Annual Shareholders Meeting' suggests it is a year-end announcement. FY 2010
2011-03-14 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.